Senate Republicans released their version of the Trump administration’s “One Big Beautiful Bill Act” on Monday with a few ...

The biopharma industry has hit a setback in its ambition to leverage President Donald Trump’s “big, beautiful bill” to amend ...

U.S. FDA grants Orphan Drug Designation to Deramiocel for the treatment of Becker Muscular Dystrophy, broadening Capricor’s ...

SENTI-202, a groundbreaking CAR NK-cell therapy, targets relapsed/refractory AML, offering hope for patients with limited ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to ...

A controversial proposal to change the Inflation Reduction Act’s pricing framework for rare disease drugs has been dropped ...

Novel chemoimmunotherapy platform aims to transform outcomes in one of the world’s deadliest cancersNEW YORK, June 17, 2025 (GLOBE NEWSWIRE) -- Medicovestor, Inc., a biotechnology company advancing ...

Diagonal Therapeutics Inc.’s DIAG-723 has been awarded orphan drug designation by the FDA for the treatment of hereditary hemorrhagic telangiectasia (HHT). Additionally, the EMA has provided a ...

Palvella Therapeutics’ drug candidate QTORIN rapamycin receives US patent: Wayne, Pennsylvania Saturday, June 21, 2025, 13:00 Hrs [IST] Palvella Therapeutics Inc, a clinical-sta ...

On June 16, 2025, RemeGen Co., Ltd. ('RemeGen', stock symbols: 688331.SH/09995.HK) announced that telitacicept (RC18; brand ...